Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide

Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathur, Abhinav, Edman, Joakim, Liang, Livia, Scott, Neil W., Watson, Henry G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713223/
https://www.ncbi.nlm.nih.gov/pubmed/36467813
http://dx.doi.org/10.1002/jha2.551
_version_ 1784841970406916096
author Mathur, Abhinav
Edman, Joakim
Liang, Livia
Scott, Neil W.
Watson, Henry G.
author_facet Mathur, Abhinav
Edman, Joakim
Liang, Livia
Scott, Neil W.
Watson, Henry G.
author_sort Mathur, Abhinav
collection PubMed
description Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single‐centre experience of 324 HC‐treated MPN patients with long‐term follow‐up, compared to 47 MPN patients not on HC. Thirty‐three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow‐up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66–48.09, p = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer.
format Online
Article
Text
id pubmed-9713223
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97132232022-12-02 Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide Mathur, Abhinav Edman, Joakim Liang, Livia Scott, Neil W. Watson, Henry G. EJHaem Short Reports Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single‐centre experience of 324 HC‐treated MPN patients with long‐term follow‐up, compared to 47 MPN patients not on HC. Thirty‐three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow‐up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66–48.09, p = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer. John Wiley and Sons Inc. 2022-09-02 /pmc/articles/PMC9713223/ /pubmed/36467813 http://dx.doi.org/10.1002/jha2.551 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Mathur, Abhinav
Edman, Joakim
Liang, Livia
Scott, Neil W.
Watson, Henry G.
Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
title Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
title_full Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
title_fullStr Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
title_full_unstemmed Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
title_short Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
title_sort skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713223/
https://www.ncbi.nlm.nih.gov/pubmed/36467813
http://dx.doi.org/10.1002/jha2.551
work_keys_str_mv AT mathurabhinav skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide
AT edmanjoakim skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide
AT lianglivia skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide
AT scottneilw skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide
AT watsonhenryg skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide

Ejemplares similares